C.F.R. homeSearch C.F.R.
C.F.R.Title 37Chapter I—United States Patent and Trademark Office, Department of CommerceSubchapter A—GeneralPart 1—Rules of Practice in Patent CasesSubpart B—National Processing Provisions

37 C.F.R. § 1.132 (2026)

Affidavits or declarations traversing rejections or objections

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1976–2026 87citing cases
At a glance

Courts have cited this section in 87 opinions since 1976, 6 of them in the last five years.

When any claim of an application or a patent under reexamination is rejected or objected to, any evidence submitted to traverse the rejection or objection on a basis not otherwise provided for must be by way of an oath or declaration under this section.

[65 FR 57057, Sept. 20, 2000]
The 20 cases that cite 37 C.F.R. § 1.132 most heavily, weighted by court and treatment. RelevanceNewestTreatment
cites § 1.132 2×cited by 250 cases
Where it cites § 1.132
“During prosecution Wands submitted a declaration under 37 C.F.R. § 1.132 providing information about all of the hybridomas that appellants had produced before filing the patent application.”
The case’s holding
Whether a patent specification enables an invention without undue experimentation is determined by weighing multiple factual considerations including the amount of guidance and the predictability of the art.
Later courts cite it for
“(1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.” · 25 citing courts
2
GREENIn re DBC, 545 F.3d 1373 (Fed. Cir. 2008).
cites § 1.132 2×cited by 67 cases
Where it cites § 1.132
“In response to the examiner’s rejection of the claims during reexamination, DBC submitted three declarations pursuant to 37 C.F.R. § 1.132 to provide objective evidence of nonobviousness.”
The case’s holding
A party generally may not challenge an agency decision on a basis that was not presented to the agency.
Later courts cite it for
“it is well-established that a party generally may not challenge an agency decision on a basis that was not presented to the agency.” · 10 citing courts
3
GREENPfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007).
cites § 1.132 1×cited by 293 cases
Where it cites § 1.132
“Along with the continuation application, Pfizer submitted a preliminary amendment and statement, and a declaration under 37 C.F.R. § 1.132 by Dr. Wells dated October 3, 1988 (“Wells Declaration”).”
The case’s holding
A patent challenger must prove by clear and convincing evidence that a skilled artisan would have been motivated to combine prior art teachings with a reasonable expectation of success.
Later courts cite it for
“show by clear and convincing evidence that a skilled artisan would have been motivated to combine the teachings of the prior art references to achieve the claimed invention, and that the skilled artisan would have had a reasonable expectation of success in doing so.” · 30 citing courts
4
GREENHyatt v. Kappos, 625 F.3d 1320 (Fed. Cir. 2010).
cites § 1.132 2×cited by 36 cases
Where it cites § 1.132
“” 37 C.F.R. § 1.132 . The Manual of Patent Examining Procedures recognizes that section 1.”
The case’s holding
Applicants may introduce new evidence in section 145 proceedings subject only to the Federal Rules of Evidence and the Federal Rules of Civil Procedure.
Later courts cite it for
“consider the proceedings before and findings of the patent office in deciding what weight to afford an applicant's newly-admitted evidence.” · 5 citing courts
5
GREENCanady v. Erbe Elektromedizin GmbH, 271 F. Supp. 2d 64 (D.D.C. 2002).
cites § 1.132 2×cited by 24 cases
Where it cites § 1.132
“Plaintiff Canady submitted to the PTO a self-declaration under 37 C.F.R. § 1.132 supporting his position that no substantial questions of patentability were raised by the references submitted by the defendants.”
The case’s holding
A court that imposed a stay of litigation has inherent power and discretion to lift the stay when changed circumstances eliminate or undermine the reasons for imposing it.
Later courts cite it for
“the same court that imposes a stay of litigation has the inherent power and discretion to lift the stay.” · 5 citing courts
6
GREENDippin' Dots v. Mosey v. Esty, Jr., 476 F.3d 1337 (Fed. Cir. 2007).
cites § 1.132 1×cited by 88 cases
Where it cites § 1.132
“DDI then filed a continuation application, amending Claim 1 by adding the “serving” step. The examiner again rejected over the Aref reference, noting that “dependent on the food product being served,” it would be obvious to serve the product in a cold, free-flowing state.”
The case’s holding
A Walker Process antitrust claim requires evidence of deceptive intent that is separable from the mere fact of a patent prosecution omission.
Later courts cite it for
“the heightened standard of materiality in a walker process case requires that the patent would not have issued but for the patent examiner's justifiable reliance on the patentee's misrepresentation or omission.” · 6 citing courts
7
REDTherasense, Inc. v. Becton, Dickinson & Co., 593 F.3d 1289 (Fed. Cir. 2010).
cites § 1.132 2×cited by 18 cases
Superseded by Therasense, Inc. v. Becton, Dickinson and Co. (2011): the Court of Appeals for the Federal Circuit's own en banc opinion in this case.
Where it cites § 1.132
“This is supported by the Declaration under 37 C.F.R. 1.132 of Gordon Sanghera which accompanies the present amendment.”
8
GREENParagon Podiatry Lab'y, Inc. v. KLM Labs., Inc., 984 F.2d 1182 (Fed. Cir. 1993).
cites § 1.132 1×cited by 252 cases
Where it cites § 1.132
“6 The district court based its holding upon (1) the applicant’s failure to disclose to the patent examiner the previously discussed sales of the Omniflex or-thotic, and (2) the applicant’s submission of deceptive affidavits in response to the patent examiner’s request for…”
The case’s holding
A judge resolves the disputed finding of intent to deceive in an inequitable conduct defense rather than a jury.
Later courts cite it for
“merely conclusory statements or completely insupportable, specious, or conflicting explanations or excuses will not suffice to raise a genuine issue of fact.” · 5 citing courts
9
GREENBristol-Myers Squibb Co. v. Teva Pharm. USA, Inc, 769 F.3d 1339 (Fed. Cir. 2014).
cites § 1.132 2×cited by 16 cases
Where it cites § 1.132
“The mechanism for providing this evidence is the submission of comparative data in affidavits or decla- rations filed pursuant to USPTO Rule 132, 37 C.F.R. §1.132 . Such data may involve new experiments per- formed on the invention and the prior art for purposes of comparison,…”
10
GREENCFMT, Inc. v. Yieldup Int'l Corp., 349 F.3d 1333 (Fed. Cir. 2003).
cites § 1.132 1×cited by 55 cases
Where it cites § 1.132
“Therefore, a reasonable examiner would not have found it important in deciding whether to allow the application.”
The case’s holding
Patent disclosure does not need to enable a perfected or commercially viable embodiment unless the claims specifically require such an embodiment.
Later courts cite it for
“title 35 does not require that a patent disclosure enable one of ordinary skill in the art to make and use a perfected, commercially viable embodiment absent a claim limitation to that effect.” · 5 citing courts
11
GREENRichardson-Vicks Inc. v. Upjohn Co., 122 F.3d 1476 (Fed. Cir. 1997).
cites § 1.132 1×cited by 147 cases
Where it cites § 1.132
“The examiner explained his change of mind: This conclusion is supported by the declarations filed under 37 CFR 1.132 and the data submitted therewith on January 14, 1992 and April 22, 1992 which establish that when certain propionic acid NSAID ingredients are combined with…”
The case’s holding
The ultimate question of whether a patent claim is obvious is a question of law that must be reviewed without deference to the trial court.
Later courts cite it for
“are but a part of the 'totality of the evidence' that is used to reach the ultimate conclusion of obviousness.” · 11 citing courts
12
GREENPharmacia & Upjohn Co. v. Mylan Pharm., Inc., 170 F.3d 1373 (Fed. Cir. 1999).
cites § 1.132 1×cited by 119 cases
Where it cites § 1.132
“Appellant relies upon his two declarations filed under 37 CFR § 1.132 in support of this assertion.”
The case’s holding
Prosecution history estoppel precludes a patentee from obtaining doctrine of equivalents coverage for subject matter relinquished during patent prosecution.
Later courts cite it for
“prosecution history estoppel precludes a patentee from obtaining under the doctrine of equivalents coverage of subject matter that has been relinquished during the prosecution of its patent application.” · 4 citing courts
13
GREENSynqor, Inc. v. Vicor Corp., 988 F.3d 1341 (Fed. Cir. 2021).
cites § 1.132 1×cited by 14 cases
Later courts cite it for
“the application of issue preclusion presents a question of law that we review de novo.” · 5 citing courts
14
GREENTelebrands Corp. v. Del Labs., Inc., 719 F. Supp. 2d 283 (S.D.N.Y. 2010).
cites § 1.132 1×cited by 38 cases
Where it cites § 1.132
“in Support of Patent Application, filed with the PTO, pursuant to 37 C.F.R. § 1.132 . Telebrands’ application repeatedly emphasized the “ergonomic” shape of the Ped Egg in order to persuade the PTO that the device contained a “useful improvement” on previously existing foot…”
The case’s holding
An exclusive licensee holding all substantial rights, including the right to enforce the licensed marks, may sue infringers in its own name, and the defendant bears the burden against the presumption of non-functionality.
Later courts cite it for
“the court may properly take judicial notice of official records of the united states patent and trademark office and the united states copyright office.” · 10 citing courts
15
YELLOWLitton Sys., Inc. v. Honeywell, Inc., 140 F.3d 1449 (Fed. Cir. 1998).
cites § 1.132 1×cited by 104 cases
Abrogated by Festo Corporation v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., A/K/A Smc Corporation, and Smc Pneumatics, Inc. on other grounds: 1 citing opinion limits it to other grounds and 1 says abrogated outright.
Where it cites § 1.132
“In addition, Litton submitted three declarations under 37 C.F.R. § 1.132 supporting its nonobviousness contentions.”
The case’s holding
Prosecution history estoppel applies to amendments made to avoid prior art, even if the amendment is characterized as being for clarity.
Later courts cite it for
“literal infringement requires that the accused device contain each limitation of the claim exactly; any deviation from the claim precludes a finding of literal infringement.” · 9 citing courts
16
GREENIn re John A. Donohue, 766 F.2d 531 (Fed. Cir. 1985).
cites § 1.132 1×cited by 92 cases
Where it cites § 1.132
“Yoshito Takeuchi, one of the authors of Nomura, to ask whether the disclosed dicarboxylic acid TMBP or dime-thyl ester TMBP compounds were ever synthesized, as indicated in Nomura.”
The case’s holding
A prior art disclosure is enabling if a person of ordinary skill can combine the publication with their own knowledge to make the invention, regardless of actual synthesis.
Later courts cite it for
“such possession is effected if one of ordinary skill in the art could have combined the publication's description of the invention with his own knowledge to make the claimed invention.” · 8 citing courts
17
GREENMilwaukee Elec. Tool Corp. v. Snap-On Inc., 271 F. Supp. 3d 990 (E.D. Wis. 2017).
cites § 1.132 1×cited by 12 cases
Where it cites § 1.132
“In so doing, the'examiner stated: “Per one of the inventors, Gary Meyer, filed declaration under 37 CFR 1.132, it seems the claimed battery pack'is incapable of delivery a useful average discharge current of 20 amps or greater.”
Later courts cite it for
“snap-on cannot skirt ipr estoppel by purporting to rely on a device without actually relying on the device itself.” · 2 citing courts
18
GREENPharmacia Corp. v. Par Pharm., Inc., 417 F.3d 1369 (Fed. Cir. 2005).
cites § 1.132 1×cited by 28 cases
Where it cites § 1.132
“Pharmacia supported its argument with a 37 C.F.R. § 1.132 declaration (the declaration) comparing the 17-phenyl compound to the 20-ethyl compound.”
19
cites § 1.132 1×cited by 74 cases
Where it cites § 1.132
“United States Patent and Trademark Office, Manual of Patent Examining Procedure § 716 (4th ed.”
The case’s holding
A proper showing of unexpected results rebuts a prima facie case of obviousness if supported by objective evidence comparing the invention to the closest prior art.
Later courts cite it for
“a proper showing of unexpected results will rebut a prima facie case of obviousness.” · 2 citing courts
20
GREENIn re Derek Anthony Costello & Robert McClean, 717 F.2d 1346 (Fed. Cir. 1983).
cites § 1.132 2×cited by 17 cases
Where it cites § 1.132
“1 The authors of that paper filed with the PTO a declaration under 37 C.F.R. § 1.132 2 on June 20, 1978, stating that the subject matter of that publication is believed to be the invention of appellants and was disclosed to the authors by appellants while all were employed at…”
Later courts cite it for
“while the filing of the original application theoretically constituted a constructive reduction to practice at that time, the subsequent abandonment of that application also resulted in an abandonment of the benefit of that filing as a constructive reduction to practice.” · 1 citing court

Show all 87 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197620012026

One bar per year. Tallest: 5 cases in 2006. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Fed. Cir.37C.C.P.A.15D. Del.5S.D.N.Y.4D.N.J.3E.D. Tex.3C.D. Cal.2D.D.C.2

The 8 courts with the most citing cases, of 24 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 87 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com